Cytori Therapeutics, Inc. (NASDAQ: CYTX) recently received a Notice of
Allowance from the U.S. Patent and Trademark Office related to uses of
the Celution® System for the treatment of bone related disorders.
Specifically, the allowed claims cover prosthetic devices that can be
seeded with adipose derived stem and regenerative cells for use in bone
healing and regeneration.
In addition, the Company received a second Notice of Allowance related
to methods of obtaining clinically safe outputs from the Celution®
System. The allowed claims cover methods of testing the Celution® output
for contaminants such as red blood cells, lipids, enzymes, aggregates,
and endotoxins, among other things.
Cytori’s intellectual property portfolio currently includes 14 issued
U.S. and international patents including U.S. Patent No. 7,514,075 (the
‘075 patent), which was recently issued on April 7, 2009. With more than
40 issued claims, the ‘075 patent expands protection for the Celution®
System. Key patent claims cover multiple reagents and additives that are
critical for optimizing intravascular delivery of the Celution® System
output for indications such as cardiovascular disease, liver disease and
renal failure.
About Cytori
Cytori develops and globally commercializes regenerative medicine
technologies, which provide real-time, point-of-care access to clinical
grade regenerative cells. Our technology is incorporated into two
product families. The Celution®-related products are sold throughout
Europe and Asia primarily into the cosmetic and reconstructive surgery
market and are under evaluation by the U.S. FDA. Our StemSource®
products are sold globally for cell banking and research applications.
We are also developing additional clinical uses of our technology for
the treatment of multiple medical conditions, including cardiovascular
disease, urinary tract disorders, and wound related conditions. To
commercialize our technology, Cytori has partnered with global and
regional leaders in healthcare such as Olympus Corporation, GE
Healthcare, and Green Hospital Supply. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements are subject to risks and
uncertainties that could cause our actual results and financial position
to differ materially. Some of these risks and uncertainties include our
history of operating losses, the need for further financing, inherent
risk and uncertainty in the protection of intellectual property rights,
regulatory uncertainties regarding the collection and results of,
clinical data, dependence on third party performance, and other risks
and uncertainties described under the "Risk Factors" in Cytori's
Securities and Exchange Commission Filings, including its annual report
on Form 10-K for the year ended December 31, 2008. Cytori assumes no
responsibility to update or revise any forward-looking statements
contained in this press release to reflect events, trends or
circumstances after the date of this press release.
Cytori Therapeutics
Investor & Media Contact:
Tom
Baker, 858-875-5258
tbaker@cytoritx.com
